
Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still plummeted nearly 10% after management dialed back earnings and growth projections for the rest of the year.
The company reported second-quarter sales of $11.14 billion, beating the consensus of $11.07 billion.